News & Investors

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Oct 29, 2013
SHELTON, Conn., Oct. 29, 2013 /PRNewswire -- Cara Therapeutics, Inc. today announced top-line results from a Phase 2 clinical trial of its novel, peripherally-acting kappa opioid receptor agonist, I.V. CR845, for the treatment of acute pain following bunionectomy. In a pre-specified analysis for patients who completed the trial ("Completer Analys...
Sep 5, 2013
SHELTON, Conn., September 5, 2013 -- Cara Therapeutics, Inc., a biopharmaceutical company developing novel peripheral analgesics to treat pain and inflammatory conditions, announced today that Derek Chalmers, Chief Executive Officer, will present a company overview at the Stifel 2013 Healthcare Conference on Wednesday, September 11, 2013 at 11:30 a...
Aug 5, 2013
SHELTON, Conn., August 5, 2013 -- Cara Therapeutics, Inc., a biopharmaceutical company developing novel peripheral analgesics to treat pain and inflammatory conditions, announced today that Derek Chalmers, Chief Executive Officer, will present a company overview at the Wedbush Securities Life Sciences Management Access Conference on Wednesday, Augu...
Apr 29, 2013
SHELTON, Conn. and OSAKA, Japan, April 29, 2013 -- Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. (Maruishi) today announced that they have entered into a License Agreement providing Maruishi with exclusive rights to develop, manufacture and commercialize Cara’s lead analgesic drug candidate, CR845, for acute pain and ur...
Jun 11, 2012
PRNewswire -- Cara Therapeutics, Inc. today announced positive results from a Phase II study for the treatment of acute post-operative pain with its novel, peptide-based, peripherally-acting kappa opioid agonist, CR845. The study successfully met its primary endpoint which measured the effect of CR845 treatment on reducing the amount of resc...
May 3, 2012
Cara Therapeutics, Inc. and Chong Kun Dang Pharmaceutical Corporation (CKD Pharm) today announced that they have entered into a licensing agreement that provides CKD Pharm with the exclusive rights to develop and market Cara’s lead analgesic drug candidate, CR845, in the Republic of Korea. Under the terms of the agreement, Cara will receiv...
Apr 3, 2012
SHELTON, Conn., April 3, 2012 — Cara Therapeutics, Inc. today announced the successful completion of a first-in-man Phase I clinical trial of an oral formulation of its peptide-based, peripherally-restricted kappa opioid receptor agonist, CR845. The trial was a single-center, double-blind, placebo-controlled study to evaluate the pharmacok...
Aug 3, 2011
Cara Therapeutics, Inc. today announced the dosing of the first patient in a Phase II clinical trial of its peripherally-selective, kappa opioid agonist, CR845, for the treatment of acute post-operative pain. The double-blind, placebo-controlled trial is expected to enroll a minimum of 200 patients at multiple clinical sites in the United States...
Jul 22, 2010
The $15 million Series D financing Cara Therapeutics Inc. closed this week will go a long way toward advancing the development of its peripherally restricted kappa opioid agonist CR845, said CEO Derek Chalmers... ...
Jul 21, 2010
Shelton, CT, July 21, 2010 /PRNewswire/ — Cara Therapeutics, Inc. announced today that it had closed on a Series D financing of $15 million. The round was led by new investor, Rho Ventures, with participation from previous investors Alta Biopharma, Ascent Biomedical Ventures, CT Innovations, Devon Park BioVentures, Healthcare Private Equi...
Feb 22, 2010
San Carlos, CA, Feb 22, 2010 /The Bernstein Report on BioBusiness/ — Cara Therapeutics, Inc. believes its CR845 kappa opioid agonist will fare better than others because the peptide is too large to cross the blood-brain barrier, meaning it should avoid the side effects and narrow therapeutic windows associated with CNS receptor activatio...
Feb 8, 2010
Shelton, CT, Feb 8, 2010 /PRNewswire-FirstCall/ — Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States...
Jan 12, 2009
Shelton, CT, Jan 12, 2009 /PRNewswire-FirstCall/ — Cara Therapeutics, Inc. today announced that it is initiating a Phase II clinical trial of its long-acting peripheral kappa opioid agonist, CR845. The Phase II multi-center, double-blind, placebo-controlled trial will be conducted in the United States and will evaluate the analgesic effica...
Aug 17, 2008
Aug 17, 2008
= add release to Briefcase